Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Enhanced Epilepsy Therapy with Genetic Analysis

12.03.2004


There are genetic differences between epilepsy patients that decide on whether medical treatment is successful or not. This is the result of a major study at the Vienna General Hospital. These new insights form the basis for an epilepsy therapy tailor-made for the needs of each individual patient. This study will be presented to the scientific community at the end of May at the largest European congress on epilepsy that will be taking place in Vienna this year.



As much as three percent of the population will contract epilepsy during the course of their lives. However, thanks to state-of-the-art medicines, two-thirds of all persons affected will be able to lead lives free of epileptic attacks, although one third respond less well to these drugs. These patients were the focus of a study with more than 630 test subjects carried out by the University Hospital of Neurology at the University Hospital of Neurology. This study was dedicated to unlocking the key to a phenomenon that has long since been known in this group of patients. Namely, why does the efficacy of drugs vary so strongly from one patient to the next? In the future, the results obtained from the study of Dr. Fritz Zimprich and his team will make it possible to make a dramatic improvement in the diagnosis of the efficacy of medical therapy.

We know that there are proteins that provide something akin to chemical detoxification and they are also to be found in the brain. These transport proteins ensure that potentially damaging substances are carried away from the cells. For a healthy organism, this protective mechanism makes a lot of sense. However, it can make it more difficult to treat diseased tissue with drugs because these proteins often transport medicines from the cells that are meant to cure them.


Dr. Zimprich, the head of the study, points out that "we have only known for a little while of the existence of these so-called multi-drug resistance proteins in the brain. We picked up on this by thinking that the known differences in drug efficacy from one epilepsy patient to another may be dependant upon how many of these proteins are active in the brain of each of these patients. In turn, the degree of activity may be impacted by minute variations in genes that code for these proteins."

There are at least two of these genes since every person has a set of two chromosomes. In this study, they compared the genetic sequence (symbolised by the letters A, C, G and T) of a very specific subsection of this pair of genes. The surprising finding was that five out of six of these epilepsy patients respond very poorly to drugs if the sequence is CGC on both subsections.

Dr. Zimprich provides further interpretation of the importance of these results: "Now, we are aware of the fact that this special section does not have a direct impact on the way the transport proteins functions. However, we think that this section may be something akin to an internal regulator that has a co-determining effect on how much of the protein is produced." In the future, we will be able to make reliable predictions on the efficacy of a medical therapy by analysing the pertinent gene sections of epilepsy patients. Beyond this, these insights will form the point of departure for future combined therapies where the transport proteins are switched off by additional therapeutic agents, thus augmenting the efficacy of traditional drugs.

Professor Christoph Baumgartner, the head of the Working Group for Clinical Epileptology, chairperson of the national organisational committee and Dr. Zimprich’s colleague, is especially proud that this study was concluded shortly before the 6th European Congress on Epileptology. "The European Congress of the International League against Epilepsy only takes place every two years and it will have its venue this year in Vienna from May 30 to June 3. This means that we will now be able to present this important research to the international scientific community in Vienna."

Till C. Jelitto | alfa
Further information:
http://www.epilepsyvienna2004.org

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>